MINISTRY OF CHEMICALS AND FERTILIZERS

• 4.1.1. NUTRIENT BASED SUBSIDY SCHEME
• To ensure balanced use of fertilizers, improve agriculture productivity, promote growth of indigenous fertilizer industry, encourage competition among fertilizer companies and to reduce the burden of subsidy.
• • Under the NBS Policy, a fixed amount of subsidy decided on annual basis is provided on each grade of the subsidized Phosphatic & Potassic (P&K) fertilizers depending upon its nutrient content.
• • Maximum Retail Price (MRP) of P&K fertilizers has been left open and the manufacturers/importers/ marketers are allowed to fix MRP of P&K fertilizers at reasonable level.
• • MRP will be decided taking into account the international and domestic prices of P&K fertilizers, exchange rate, and inventory level in the country.
• • 22 grades of P&K fertilizers namely DAP, MAP, TSP, MOP, Ammonium Sulphate, SSP and 16 grades of NPKS (Nitrogen (N), Phosphate (P), Potash (K) and Sulphur (S)) complex fertilizers are covered under the NBS Policy.
• • Recently, Cabinet Committee on Economic Affairs (CCEA) also approved inclusion of a complex fertilizer namely Ammonium Phosphate under NBS Scheme.
• 4.1.2. UREA SUBSIDY IN INDIA
• • Urea Subsidy is a part of Central Sector Scheme of Department of Fertilizers
• • Urea is being provided to the farmers at a statutorily notified Maximum Retail Price (MRP).
• • The difference between the delivered cost of Fertilizers at farm gate and net market realization by the urea units is given as subsidy to the Urea manufacturer/Importer by the Govt. of India. So, it also includes freight subsidy for movement of urea across the country.
• • Accordingly, farmers are getting Urea at affordable MRP because of the subsidy provided by the Government.
• 4.1.3. CITY COMPOST SCHEME
• To support Swachh Bharat Mission and provide City Compost at subsidized rates to farmers.
• Under the scheme, a market development assistance of Rs. 1500 per tonne of city compost for scaling up production and consumption of the product, is being provided.
• Promotion of city compost will be done by fertilizer companies and marketing entities. Companies will also adopt villages for promoting the use of compost.
• An appropriate BIS standard/ Eco-Mark will be developed to ensure better market acceptance. 
• 4.2. DEPARTMENT OF PHARMACEUTICALS
• 4.2.1. SCHEME FOR PROMOTION OF MEDICAL DEVICE PARKS
• The Scheme aims to promote Medical Device Parks in the country in partnership with the States
• It will be implemented by a State Implementing Agency (SIA) from 2020-21 to 2024-25.
• A maximum grant-in-aid of Rs.100 crore per park will be provided to the States.
• The target is to provide financial assistance for Common Infrastructure Facilities for 4 Medical Device parks.
• It is expected to reduce manufacturing cost of medical devices in the country.
• Note: India depends on imports up to an extent of 85% of total domestic demand of medical devices.
• 4.2.2. PROMOTION OF BULK DRUG PARKS
• To develop 3 mega Bulk Drug parks in India in partnership with States to reduce manufacturing cost of bulk drugs in the country and dependency on other countries for bulk drugs
• Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
• Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
• The scheme will be implemented by State Implementing Agencies (SIA) to be set up by the respective State Governments
• A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.
• Despite India being the 3rd largest pharmaceutical industry in the world by volume, it is significantly dependent on import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs the import dependence is 80 to 100%.

• 4.2.3. PRODUCTION LINKED INCENTIVE SCHEME (FOR PROMOTION OF DOMESTIC MANUFACTURING OF CRITICAL KSMS/DRUG INTERMEDIATES AND APIS)
• For promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs by attracting large investments in the sector to ensure their sustainable domestic supply and thereby reduce India's import dependence
• Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
• Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.
• Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs.
• The scheme will be implemented through a Project Management Agency (PMA) to be nominated by the Department of Pharmaceuticals.
• A sum of Rs. 6,940 crore has been approved for next 8 years.
• 4.2.4. PRODUCTION LINKED INCENTIVE (PLI) SCHEME (FOR PROMOTING DOMESTIC MANUFACTURING OF MEDICAL DEVICES)
• The Scheme aim to boost domestic manufacturing by attracting large investments in medical device sector
• PLI Scheme for promoting domestic manufacturing will be implemented by a Project Management Agency (PMA) to be nominated by Department of Pharmaceuticals from 2020-21 to 2024-25.
• Under the Scheme, incentive @ 5% of incremental sales over base year 2019-20 will be provided on the segments of medical devices identified
• It seeks to provide assistance to about 25-30 manufacturers under the following categories of medical devices:
• o Cancer care/Radiotherapy medical devices
• o Radiology & Imaging medical devices
• o Nuclear Imaging Devices etc.
• It will lead to expected incremental production of Rs. 68,437 crore over a period of five years.
• 4.2.5. PRADHAN MANTRI BHARTIYA JANAUSHADI PARIYOJANA (PMBJP)
• Making quality medicines available at affordable prices for all, particularly the poor and disadvantaged, through exclusive outlets “Pradhan Mantri Bhartiya Janaushadhi Kendras”, so as to reduce out of pocket expenses in healthcare.
• • To provide generic drugs which are available at lesser prices but are equivalent in quality and efficacy as expensive branded drugs.
• • Create awareness about generic medicines through education and publicity so that quality is not synonymous with only high price
• • State Governments or any organization / reputed NGOs / Trusts / Private hospitals / Charitable institutions / Doctors / Unemployed pharmacist/ individualentrepreneurs are eligible to apply for new Pradhan Mantri Bhartiya Janaushadhi Kendras.
• • An amount of Rs.2.5 lakhs shall be extended to NGOs/agencies/ individuals establishing Janaushadhi Kendras (JAK) in government hospital premises where space is provided free of cost by Govt. to operating agency.
• • Implementing Agency - Bureau of Pharma PSUs of India (BPPI)
• • JANAUSHADI SUVIDHA: Centre has launched the oxo-biodegradable sanitary napkins under the PMBJP. It will ensure ‘Swachhta, Swasthya and Suvidha’ for underprivileged women. It has been manufactured by Bureau of Pharma Public Sector Undertaking of India.
• 4.2.6. SCHEME FOR DEVELOPMENT OF PHARMACEUTICAL INDUSTRY
• To ensure drug security in the country by increasing the efficiency and competitiveness of domestic pharmaceutical industry
• Central Sector Scheme with a total financial outlay of Rs. 480 Crore.
• It has following sub-schemes:
• o Assistance to Bulk Drug Industry for Common Facility Centre: financial assistance in the form of one time grant (maximum 100 crore per CFC or 70% of cost whichever is less) would be provided for creation of common facilities in any upcoming Bulk Drug Park promoted by State Governments.
• o Assistance to Medical Device Industry for Common Facility Centre: financial assistance in the form of one time grant (maximum 25 crore per CFC or 70% of cost whichever is less) would be provided for creation of common facilities in any upcoming Medical Device Park promoted by State Governments
• o Pharmaceuticals Technology Upgradation Assistance Scheme: to facilitate Small and Medium Pharma Enterprises (SMEs) to upgrade their plant and machinery. Assistance in the form of interest subvention will be provided to 250 pharma SMEs.
• o Assistance for Cluster Development: an existing scheme Cluster Development Programme for Pharma Sector (CDP-PS) has been subsumed under the umbrella scheme. Grant-in-aid of 20crore or 70% of project cost whichever is less is provided.
• o Pharmaceutical Promotion Development Scheme: aims at the promotion, development and export promotion in Pharmaceutical sector by extending financial support.
• 4.2.7. OTHER SCHEMES
• Pharma Jan Samadhan
• • It is a web enabled system for redressal of consumers’ grievances relating to pricing and availability of medicines, created by National Pharmaceutical Pricing Authority (NPPA).
• • It would serve as a robust e-governance tool for effective implementation of the Drugs (Price Control) Order 2013.
• • NPPA will initiate action on any complaint within 48 hrs of its receipt.
• ‘Pharma Sahi Daam’ Mobile App
• • It is a mobile App. developed by NPPA which shows the MRP fixed by NPPA for various scheduled drugs on real time basis. 
• 4.3. DEPARTMENT OF CHEMICALS & PETROCHEMICALS
• 4.3.1. PLASTIC PARKS SCHEME
• To increase competitiveness and investments, achieve environmentally sustainable growth and adopt the cluster development approach to consolidate the capacities in plastic sector. It also seeks to reduce plastic imports.
• • It was envisaged in the National Plastic Park Policy in 2010 which was modified in 2013.
• • The scheme support setting up of a need based “Plastic Parks’ an eco-system with requisite state of the art infrastructure and enabling common facilities to assist the sector move up the value chain and contribute to the economy more effectively.
• • Funding Pattern: The centre will provide 50% of the project cost subject to a ceiling of Rs. 40 crore per project and rest will be contributed by the Special Purpose Vehicle (SPV) formed by State Government or State Industrial Development Corporation.